Short-term effects of perindopril-amlodipine vs perindopril-indapamide on blood pressure control in sub-Saharan type 2 diabetic individuals newly diagnosed for hypertension: A double-blinded randomized controlled trial
Autor: | Eugene Sobngwi, Chris Nadège Nganou-Gnindjio, Francois Folefack Kaze, Aurel T. Tankeu, Martine Etoa, Ariane Nkamgna, Jean Claude Mbanya, Eliane Ngassam, Merveille Kouam, Andre Pascal Kengne, Liliane Mfeukeu-Kuate, Mesmin Dehayem, Ba Hamadou |
---|---|
Rok vydání: | 2018 |
Předmět: |
Male
medicine.medical_specialty Endocrinology Diabetes and Metabolism Blood Pressure Type 2 diabetes Comorbidity Therapeutics 030204 cardiovascular system & hematology law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Double-Blind Method law Internal medicine Internal Medicine medicine Perindopril Humans 030212 general & internal medicine Amlodipine Adverse effect Perindopril/indapamide Africa South of the Sahara Antihypertensive Agents business.industry Indapamide Blood Pressure Monitoring Ambulatory Middle Aged medicine.disease Drug Combinations Blood pressure Treatment Outcome Diabetes Mellitus Type 2 Hypertension Female Drug Monitoring Cardiology and Cardiovascular Medicine business medicine.drug |
Zdroj: | J Clin Hypertens (Greenwich) |
ISSN: | 1751-7176 |
Popis: | Poor blood pressure (BP) control contributes to complications in sub-Saharan African (SSA) type 2 diabetic individuals. Experts have advocated the use of combination therapies for effective BP control in these patients. The suggested combinations should include a RAAS antagonist and either a CCB or a thiazide diuretic; however, their efficacy is yet to be established in SSA. We investigated the short-term effects of two combination therapies on BP control in SSA type 2 diabetic individuals. This was a double-blinded randomized controlled trial conducted at the Yaounde Central Hospital (Cameroon) from October 2016 to May 2017. We included type 2 diabetic patients, newly diagnosed for hypertension. After baseline assessment and 24-hour ABPM, participants were allocated to receive either a fixed combination of perindopril + amlodipine or perindopril + indapamide for 42 days. Data analyses followed the intention-to-treat principle. We included fifteen participants (8 being females) in each group. Both combinations provided good circadian BP control after 6 weeks with similar efficacy. Twenty-four-hour SBP dropped from 144 to 145 mm Hg vs 128 to 126 mm Hg with perindopril-amlodipine and perindopril-indapamide, respectively (P = 0.003 for both groups). Twenty-four-hour DBP dropped from 85 to 78 mm Hg (P = 0.013) vs 89 to 79 mm Hg (P = 0.006) in the same respective groups. No significant adverse effect was reported. A fixed initial combination of perindopril-amlodipine or perindopril-indapamide achieved similar effective BP control after 6 weeks in SSA type 2 diabetic individuals with newly diagnosed hypertension. Therefore, these combinations can be used interchangeably in this indication. |
Databáze: | OpenAIRE |
Externí odkaz: |